News
ANTX
15.49
0.00%
0.00
*AN2 Therapeutics Projects Existing Cash, Cash Equivalents and Investments Will Sustain Ops Into 2028
Dow Jones · 11/12 21:11
*AN2 Therapeutics Advancing Phase 1 Program in Chagas Disease; Phase 2 Planning Underway >ANTX
Dow Jones · 11/12 21:10
*AN2 Therapeutics 3Q Loss/Shr 31c >ANTX
Dow Jones · 11/12 21:01
*AN2 Therapeutics 3Q Loss $9.35M >ANTX
Dow Jones · 11/12 21:01
Press Release: AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Dow Jones · 11/12 21:01
AN2 Therapeutics Announces Collaboration Agreement With GSK To Develop New Therapies For TB
Benzinga · 11/10 12:11
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/23 21:07
*AN2 Therapeutics: Cash Runway Anticipated to Fund Ops Into 2028 >ANTX
Dow Jones · 08/12 20:25
*AN2 Therapeutics 2Q Loss $6.46M >ANTX
Dow Jones · 08/12 20:13
*AN2 Therapeutics 2Q Loss/Shr 21c >ANTX
Dow Jones · 08/12 20:13
Press Release: AN2 Therapeutics Reports Second -2-
Dow Jones · 08/12 20:01
Press Release: AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Dow Jones · 08/12 20:01
AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime
Benzinga · 06/30 11:11
*AN2 Therapeutics: Cash Runway Anticipated to Fund Ops Into 2028 >ANTX
Dow Jones · 05/13 20:15
*AN2 Therapeutics 1Q Loss $10.6M >ANTX
Dow Jones · 05/13 20:02
Press Release: AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Dow Jones · 05/13 20:01
AN2 Therapeutics Is Maintained at Market Outperform by JMP Securities
Dow Jones · 05/05 13:42
AN2 Therapeutics Price Target Cut to $2.00/Share From $5.00 by JMP Securities
Dow Jones · 05/05 13:42
JMP Securities Maintains Market Outperform on AN2 Therapeutics, Lowers Price Target to $2
Benzinga · 05/05 13:31
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 05/01 21:06
More
Webull provides a variety of real-time ANTX stock news. You can receive the latest news about Anthem through multiple platforms. This information may help you make smarter investment decisions.
About ANTX
Anthem, Inc. is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. It also provides an array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. It provides an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits and radiology benefit management.